Bile acids are metabolic links between hosts and their gut microbiomes, yet little is known about 27 the roles they play in microbe-to-microbe interactions. Here we present a study designed to 28 investigate the effect that a common probiotic, Lactobacillus acidophilus, has on microbial 29
INTRODUCTION 45
The human gastrointestinal (GI) tract is a complex ecosystem that functions in symbiosis with 46 oral and intestinal microbiomes 1,2 . It has long been recognized that the composition of the gut 47 microbiome has a significant effect on host digestion but more recent research has implicated the 48 microbiome in human health and disease states that include cardiovascular disease risk 3 , 49 neurological function 4 , and autoimmunity 5 . Rapid gains in knowledge of host-microbiome 50 associations will undoubtedly lead to new practical applications 6 . Of these, the use of probiotics 51 to modulate both the function and composition of gut microbiomes is especially promising 7, 8 . 52
Probiotic supplementation likely reduces the risk of developing antibiotic associated diarrhea 9 53 and necrotizing enterocolitis in infants 10 . However, the therapeutic opportunities for probiotics 54 are advancing to more precisely target specific processes carried out by the gut microbiome to 55 impart health benefits beyond enhanced digestion [11] [12] [13] . Probiotic therapies are being explored 56 relieve symptoms of autism 14 , depression 4 , autoimmune diseases 15, 16 , and irritable bowel 57 syndrome 17 among many other conditions with positive -albeit conflicting -results. The 58 efficacy of probiotic treatments is variable. Differing results can obviously arise from 59 inconsistent study design -e.g., probiotic strain, dose -trial size, but they are also indicative of a 60 large scientific knowledge gap and incomplete understanding of the mechanisms by which 61 probiotics impact the GI-tract microbial ecosystem. 62
There are many hypotheses about the modes of action by which the gut microbiome and 63 probiotic microbes impact human health. One proposed model is through modulation of the host 64 immune system 18 , which has been concluded from studies that showed probiotic treatments 65 affecting host immune function in humans facing pathogenic challenges [19] [20] [21] or with autoimmune 66 disorder 15, 16, 22 . Another hypothesis is that probiotics increase microbial competition within the 67 intestinal ecosystem, thereby making it more difficult for pathogenic bacteria to survive 23, 24 . 68
Studies have also speculated that observed therapeutic action from probiotics results from their 69 effect on the intestinal physiology by modulating endothelial junctions 25 and the mucosal 70 lining 12,25 through a variety of proposed metabolic pathways. Another possible mode of action 71 for probiotics is through bile acids. It has long been known that bile acids are important linkers 72 between host and gut microbes. Intestinal bacteria produce secondary bile acids by 73 deconjugation, reduction, oxidation, and epimerization of their host's primary bile acids. Many 74 probiotics can alter bile acid pools in humans 26, 27 . 75
The primary bile acids (cholic acid and chenodeoxycholic acid) are synthesized in human 76 hepatocytes and conjugated to the amino acids glycine and taurine to increase solubility 27, 28 . 77
They are then released into the duodenum and moved through the small intestine to assist 78 emulsification of dietary lipophilic substances 29 . Approximately 95% of the bile acids are then 79 passively reabsorbed in transit through the small intestine, resulting in approximately 5% (400-80 800 mg) passed on to the colon 27 . In the colon, these bile acids are rapidly deconjugated by the 81 microbiome and reduced, oxidized and epimerized to a variety of secondary bile acids 27 . These 82 secondary bile acids are known to have diverse effects on human health ranging from direct 83 cytotoxicity 30 , to altered probability of cancer 31 , to hormonal function as cell messengers 29, [32] [33] [34] . 84
More recently, this list of known host-related effects has grown to include modulating the 85 composition and function of the gut microbiome 35,36 -e.g., by disassembling lipid membranes. 86
The intestinal microbiome represents a major modifier of the human bile acid pool. This 87 is evinced by the fact that bile in the gall bladder is comprised of 70% primary bile acids but 88 only 4% primary bile acids in the feces 27 . Not only does the microbiome determine bile acid 89 composition, but bile acids also direct microbial communities 37 . For example, studies have 90 
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L. acidophilus quenches secondary bile acid production. Ursocholic acid was produced in the 168 3MC ( Fig. 2A) , but not by any one species grown under axenic conditions. Hence, ursocholic 169 acid was produced by a multispecies synthesis route that required at least two species from our 170 model consortium. Addition of the probiotic, L. acidophilus quenched the production of 171 ursocholic acid to negligible levels as compared to those measured in the 3MC (Fig. 2b) . In 172 addition to ursocholic acid production, L. acidophilus also attenuated growth of B. obeum and C. 173 aerofaciens as observed in the 3MC + L species-specific growth dynamics, which were in stark 174 contrast to the 3MC (Fig.2c) . Within the 3MC + L, L. acidophilus became a dominant member 175 of the community, but in the absence of the probiotic, the 3MC was dominated by B. obeum with 176 C. scindens showing the lowest relative abundance in both consortia. 177
The dynamic profiles of bile acids and bacterial species were correlated for each 178 treatment group, 3MC and 3MC + L (Fig. 2d) , respectively. Pearson's correlations were 179 determined between species and for species to bile acids but not between bile acids. The results 180
show that ursocholic acid shared strong positive correlations (Pearson's coefficient; r > 0.85) 181 with the abundances of C. aerofaciens and B. obeum in the 3MC. As expected, cholic acid 182 showed strong negative correlations with C. aerofaciens and B. obeum within the 3MC, 183 establishing that it was the most likely substrate for ursocholic acid synthesis. Cholic acid, was 184 not correlated with C. scindens, implying that this species may not have been involved in 185 production of secondary bile acids directly from cholic acid. The lack of C. scindens' 186 participation in secondary bile acid synthesis in the 3MC was also evinced by its strong negative 187 correlation with deoxycholic acid, a known 7α-dehydroxylation product of C. scindens that 188 utilizes cholic acid as the substrate 27 . 189 given that bile acid profiles change by increasing abundance of secondary bile acids 49 . To 265 investigate the clinical relevance of ursocholic acid, we leveraged access to a cohort of patients 266 that had undergone gastric bypass surgery. Targeted measurements of ursocholic acid were 267 performed and compared in fecal samples collected from 24 patients that underwent RYGB 268 surgery: 10 patients with normal weight and 14 morbidly obese controls, which included those 269 scheduled for surgery 44 . We found that the abundance of ursocholic acid corresponded with 270 obesity and the success of gastric bypass surgical procedures (Fig. 4) . Success was defined when 271 patients exhibited at least 50% excess weight loss and less than 20% regain. Ursocholic acid 272 levels were significantly higher in the morbidly obese controls (pre-surgery) compared to 273 patients that had experienced successful gastric bypass surgery. There was no statistically 274
Figure 4. Normalized abundance of ursocholic acid in feces of patients who had undergone gastric bypass surgery -Roux-en-Y gastric bypass (RYGB) -as compared to normal weight and obese controls. Unpaired two-tailed t-tests were used to infer a statistical difference between the means of the obese controls -a group that contained pre-operative patients -and those that experience successful RYGB (p < 0.005). Different ursocholic acid abundances were also observed -albeit statistically less conclusive -between successful and unsuccessful RYGB patients (p < 0.076). The data derived from our clinical study showed that ursocholic acid is in fact present 307 and abundant within the human GI-tract and its relative abundances change when drastic changes 308 to microbiome occur (pre-and post-bariatric surgery) 44 . Our limited understanding of the role 309 that ursocholic acid plays in human health and specifically the host-microbiome interactions that 310 lead to its production represent a major knowledge gap. This is punctuated by the fact that our 311 current study -and a previous study 73 whether the CAP-enriched alcohol dehydrogenase (A5ZM66; RUMOBE_00083) and alcohol-335 aldehyde dehydrogenase (A5ZNA3; RUMOBE_00470) were responsible for the hypothesized 336 reactions. Certainly, other proteins were enriched by CAP (Table S2 ), yet these were the only B. 337 obeum proteins annotated with an enzymatic function capable of alcohol-aldehyde 338 interconversion. We cannot rule out the possibility that enriched proteins of unknown function 339 participated in the observed reaction. However, there is some precedent for associating 340 secondary bile acid synthesis genes with alcohol dehydrogenases. BaiA proteins from C. 341 scindens, encoding for 3α-HSDH proteins, have previously been shown to align well to short 342 chain alcohol dehydrogenases in Eubacterium sp. Strain VPI 12708 and to alcohol/polyol 343 dehydrogenase genes 77, 78 . We chose to use C. scindens in the 3MC because it has genes that 344 encode for Bai proteins and express HSDH proteins. In fact, the C. scindens reference proteome 345 (VPI 12708) does contain a putative 7α-HSDH (UniProtKB -Q03906); however, C. scindens 346 abundances and correlation-based inferences from this study did not provide evidence of C. 347 scindens' participation in the transformation of cholic acid to secondary acids. Our conclusion 348 was that C. scindens played a minor role in the system and was largely outcompeted by other 349 members. . It is possible that the cessation of ursocholic acid production or 362 increased abundances of Lactobacillus sp. could result in better control over weight loss. We also 363 note that there is some precedent derived from mouse models for the idea that probiotics or 364 introduction of non-adapted microbial taxa can modulate a hosts' microbiome 7 and microbe-365 associated bile acid pool 79 . 366 Table S3 targeting rpoB. 396 PCR reactions were run using the FAST cycling conditions: initial denaturation was done for 20 397 seconds at 95 °C followed by 40 cycles of denaturation (95 °C for 3 seconds), annealing (60 °C 398 for 30 seconds). The output from the real-time PCR assays were C T values that represent the 399 PCR cycle at which the amplification crosses a given threshold (0.1). All C T values in Table S4 ; 400 data are plotted and analyzed as inverse C T representing the relevant abundance 66, 80 assuming 401 equal between species in the consortia. Bile acid photoaffinity probes and proteomics. Custom photoaffinity probes were synthesized 443 as derivatives of cholic and deoxycholic acid for this study as described in detail within the 444 supplementary materials. Bacterial lysate samples were normalized to 500 µL 1.8 mg/mL 445 proteome in PBS buffer. Cholic acid photoaffinity probe (CAP) or an equal volume of DMSO 446 control was incubated with proteome for 60 min at 37 °C. Final DMSO concentration was 1%. 447 Samples were exposed to UV light (wavelength: 365nm; 115V, 15W) using a Fisher UVP95 448 lamp (Fisher Scientific, Hampton, NH, USA) for 7 minutes on ice. Subsequent to UV irradiation, 449 the samples were subjected to click chemistry, with final concentrations of reagents being: 450 biotin-azide (60 µM) in DMSO, sodium ascorbate (10 mM), THPTA (4 mM), and CuSO 4 (8 451 mM). Each reagent was added individually in that sequence, vortexed, centrifuged, and 452 incubated at room temperature in the dark for 90 min. 800 µL of pre-chilled MeOH was then 453 added to each sample and incubated at -80 °C freezer for 30 min to induce protein precipitation. 454
Samples were centrifuged at 14,000 x g at 4°C for 5 min. The supernatant was discarded, and the 455 pellet was allowed to air-dry for 5 min. Samples were reconstituted and sonicated in 520 µl SDS 456
(1.2%) in PBS; followed by incubation at 95 °C for 2 min. Samples were centrifuged at 14,000 x 457 g for 4 min at room temperature. Protein concentrations were determined via BCA assay and 458 samples were normalized to a volume of 500 µL at 1.2 mg/mL. Trypsin digestion was performed 459 on protein bound to 100 µL Streptavidin-agarose beads. Peptides were reconstituted by adding 460 40 µl of 25 mM NH 4 HCO 3 and heating the samples at 37°C for 5 min. Samples were transferred 461 to ultracentrifuge tubes and were centrifuged at 100,000 x g to remove debris. 25 µL was added 462 to glass vials for storage at -20 °C until analysis. All proteomics samples prepared for LC-MS 463 were analyzed using a Velos Orbitrap MS as previously described 85, 86 . 464 465 Clinical data and experimentation. Fecal samples were collected from patients at the Mayo 466
Clinic, Scottsdale, AZ, USA. The metabolomics assays were performed at the Pacific Northwest 467
National Laboratory by the methods described above. The experimental design has been 468 previously described 44 were fit to the log of the exponential growth phase of microbial consortia, and for each 477 regression, the goodness of fit and the probability of observing a similar slope if the true slope 478 coefficient was zero was reported. Global proteomics was used to identify proteins enriched by 479 the CAP probes, by selecting proteins with a fold-change increase of >100 and a t-test p-value of 480 
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